Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer https://t.co/lJ9OVwyte9
792 followers
1,804 followers
RT @TheLancetOncol: #AACR18 Updated efficacy results on durvalumab + tremelimumab in #NSCLC phase 1b trial -OS data still immature See pr…
4,238 followers
RT @TheLancetOncol: #AACR18 Updated efficacy results on durvalumab + tremelimumab in #NSCLC phase 1b trial -OS data still immature See pr…
199 followers
RT @TheLancetOncol: #AACR18 Updated efficacy results on durvalumab + tremelimumab in #NSCLC phase 1b trial -OS data still immature See pr…